{"title":"癌症呼吸困难综合姑息治疗结果量表的微小临床重要差异。","authors":"Yoshinobu Matsuda, Masanori Mori, Akihiro Tokoro, Yoshihiko Taniguchi, Sayo Aiki, Yusuke Takagi, Daisuke Kiuchi, Kozue Suzuki, Madoka Ito, Shunsuke Oyamada, Keisuke Ariyoshi, Takashi Yamaguchi","doi":"10.1016/j.jpainsymman.2025.06.010","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Dyspnea is a common and distressing symptom in patients with cancer. The Integrated Palliative care Outcome Scale (IPOS) provides health care providers with a proxy tool for assessing dyspnea; however, the minimal clinically important difference (MCID) in the IPOS for dyspnea is unknown.</p><p><strong>Objectives: </strong>To determine the MCID in the IPOS improvement for dyspnea.</p><p><strong>Methods: </strong>This secondary analysis used data from a multicenter prospective observational study initially designed to evaluate the effectiveness and safety of opioids for dyspnea in patients with cancer. We included patients with available IPOS scores and Patient's Global Impression (PGI) at baseline and 24, 48, and 72 h after starting opioid therapy, comprising cohorts 1, 2, and 3, respectively. The MCID for IPOS improvement in dyspnea was determined using a sensitivity-specificity approach, specifically Youden's J statistic and the top-left approach.</p><p><strong>Results: </strong>A total of 354, 308, and 272 patients were included in cohorts 1, 2, and 3, respectively. Based on Youden's J statistic, the optimal MCID cutoff for improvement in the IPOS score for dyspnea was ≥+1 in all cohorts. The sensitivities of these cutoffs were 0.86, 0.885, and 0.909 and the specificities were 0.770, 0.593, and 0.560 for cohorts 1, 2, and 3, respectively. The top-left approach confirmed this MCID cutoff of ≥+1 in all cohorts.</p><p><strong>Conclusion: </strong>The MCID for IPOS improvement in dyspnea was determined to be ≥+1 across all time points. This can facilitate the design and interpretation of future studies using IPOS scores as study outcomes.</p><p><strong>Clinical trial registration: </strong>UMINCTR: UMIN 000038918.</p>","PeriodicalId":16634,"journal":{"name":"Journal of pain and symptom management","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Minimal Clinically Important Difference in the Integrated Palliative Care Outcome Scale for Cancer Dyspnea.\",\"authors\":\"Yoshinobu Matsuda, Masanori Mori, Akihiro Tokoro, Yoshihiko Taniguchi, Sayo Aiki, Yusuke Takagi, Daisuke Kiuchi, Kozue Suzuki, Madoka Ito, Shunsuke Oyamada, Keisuke Ariyoshi, Takashi Yamaguchi\",\"doi\":\"10.1016/j.jpainsymman.2025.06.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Dyspnea is a common and distressing symptom in patients with cancer. The Integrated Palliative care Outcome Scale (IPOS) provides health care providers with a proxy tool for assessing dyspnea; however, the minimal clinically important difference (MCID) in the IPOS for dyspnea is unknown.</p><p><strong>Objectives: </strong>To determine the MCID in the IPOS improvement for dyspnea.</p><p><strong>Methods: </strong>This secondary analysis used data from a multicenter prospective observational study initially designed to evaluate the effectiveness and safety of opioids for dyspnea in patients with cancer. We included patients with available IPOS scores and Patient's Global Impression (PGI) at baseline and 24, 48, and 72 h after starting opioid therapy, comprising cohorts 1, 2, and 3, respectively. The MCID for IPOS improvement in dyspnea was determined using a sensitivity-specificity approach, specifically Youden's J statistic and the top-left approach.</p><p><strong>Results: </strong>A total of 354, 308, and 272 patients were included in cohorts 1, 2, and 3, respectively. Based on Youden's J statistic, the optimal MCID cutoff for improvement in the IPOS score for dyspnea was ≥+1 in all cohorts. The sensitivities of these cutoffs were 0.86, 0.885, and 0.909 and the specificities were 0.770, 0.593, and 0.560 for cohorts 1, 2, and 3, respectively. The top-left approach confirmed this MCID cutoff of ≥+1 in all cohorts.</p><p><strong>Conclusion: </strong>The MCID for IPOS improvement in dyspnea was determined to be ≥+1 across all time points. This can facilitate the design and interpretation of future studies using IPOS scores as study outcomes.</p><p><strong>Clinical trial registration: </strong>UMINCTR: UMIN 000038918.</p>\",\"PeriodicalId\":16634,\"journal\":{\"name\":\"Journal of pain and symptom management\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pain and symptom management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jpainsymman.2025.06.010\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pain and symptom management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpainsymman.2025.06.010","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Minimal Clinically Important Difference in the Integrated Palliative Care Outcome Scale for Cancer Dyspnea.
Context: Dyspnea is a common and distressing symptom in patients with cancer. The Integrated Palliative care Outcome Scale (IPOS) provides health care providers with a proxy tool for assessing dyspnea; however, the minimal clinically important difference (MCID) in the IPOS for dyspnea is unknown.
Objectives: To determine the MCID in the IPOS improvement for dyspnea.
Methods: This secondary analysis used data from a multicenter prospective observational study initially designed to evaluate the effectiveness and safety of opioids for dyspnea in patients with cancer. We included patients with available IPOS scores and Patient's Global Impression (PGI) at baseline and 24, 48, and 72 h after starting opioid therapy, comprising cohorts 1, 2, and 3, respectively. The MCID for IPOS improvement in dyspnea was determined using a sensitivity-specificity approach, specifically Youden's J statistic and the top-left approach.
Results: A total of 354, 308, and 272 patients were included in cohorts 1, 2, and 3, respectively. Based on Youden's J statistic, the optimal MCID cutoff for improvement in the IPOS score for dyspnea was ≥+1 in all cohorts. The sensitivities of these cutoffs were 0.86, 0.885, and 0.909 and the specificities were 0.770, 0.593, and 0.560 for cohorts 1, 2, and 3, respectively. The top-left approach confirmed this MCID cutoff of ≥+1 in all cohorts.
Conclusion: The MCID for IPOS improvement in dyspnea was determined to be ≥+1 across all time points. This can facilitate the design and interpretation of future studies using IPOS scores as study outcomes.
期刊介绍：
The Journal of Pain and Symptom Management is an internationally respected, peer-reviewed journal and serves an interdisciplinary audience of professionals by providing a forum for the publication of the latest clinical research and best practices related to the relief of illness burden among patients afflicted with serious or life-threatening illness.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
